Peroxisome proliferator-activated receptor-α and -γ rnRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection

被引:100
作者
De Gottardi, A
Pazienza, V
Pugnale, P
Bruttin, F
Rubbia-Brandt, L
Juge-Aubry, CE
Meier, CA
Hadengue, A
Negro, F
机构
[1] Hop Univ Geneva, Serv Gastroenterol & Hepatol, Geneva, Switzerland
[2] Hop Univ Geneva, Serv Patol Clin, Geneva, Switzerland
[3] Hop Univ Geneva, Serv Endocrinol, Geneva, Switzerland
关键词
D O I
10.1111/j.1365-2036.2006.02729.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Steatosis in chronic hepatitis C is associated with inflammation and accelerated fibrogenesis. Aim To assess the contribution of peroxisome proliferator-activated receptor, alpha and -gamma to the pathogenesis of hepatitis C virus associated steatosis is unknown. Methods We measured peroxisome proliferator- activated receptor (PPAR)-alpha. and -gamma mRNA by quantitative polymerase chain reaction in liver biopsies of 35 genotype 1 and 22 genotype 3 infected patients and in Huh7 cells expressing hepatitis C virus 1b or 3a core protein. Results PPAR-a mRNA was significantly reduced in livers of patients with genotype 3 compared with genotype 1. Steatosis was associated to a decreased expression of PPAR-alpha in genotype 1, but not in genotype 3. PPAR-gamma expression was significantly lower in genotype 3 compared with genotype 1 and steatosis was associated to decreased levels of PPAR-gamma, but only in genotype 1. There was no significant relationship between PPARs mRNA levels and liver activity or fibrosis. Expression of the hepatitis C virus 3a core protein was associated with an increase in triglyceride accumulation and with a significant reduction of PPAR-gamma mRNA compared with hepatitis C virus 1b. Conclusions The presence of steatosis and hepatitis C virus genotype 3 are both associated with a significant down-regulation of PPARs. These receptors, and also additional factors, seem to play a role in the pathogenesis of hepatitis C virus-associated steatosis.
引用
收藏
页码:107 / 114
页数:8
相关论文
共 38 条
[21]   Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone [J].
Neuschwander-Tetri, BA ;
Brunt, EM ;
Wehmeier, KR ;
Oliver, D ;
Bacon, BR .
HEPATOLOGY, 2003, 38 (04) :1008-1017
[22]   Prognosis of chronic hepatitis C:: Results of a large, prospective cohort study [J].
Niederau, C ;
Lange, S ;
Heintges, T ;
Erhardt, A ;
Buschkamp, M ;
Hürter, D ;
Nawrocki, M ;
Kruska, L ;
Hensel, F ;
Petry, W ;
Häussinger, D .
HEPATOLOGY, 1998, 28 (06) :1687-1695
[23]   Role of alcohol in the progression of liver disease caused by hepatitis C virus infection [J].
Ostapowicz, G ;
Watson, KJR ;
Locarnini, SA ;
Desmond, PV .
HEPATOLOGY, 1998, 27 (06) :1730-1735
[24]   The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients [J].
Patton, HM ;
Patel, K ;
Behling, C ;
Bylund, D ;
Blatt, LM ;
Vallée, M ;
Heaton, S ;
Conrad, A ;
Pockros, PJ ;
McHutchison, JG .
JOURNAL OF HEPATOLOGY, 2004, 40 (03) :484-490
[25]   Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion:: a model of viral-related steatosis [J].
Perlemuter, G ;
Sabile, A ;
Letteron, P ;
Vona, G ;
Topilco, A ;
Chrétien, Y ;
Koike, K ;
Pessayre, D ;
Chapman, J ;
Barba, G ;
Bréchot, C .
FASEB JOURNAL, 2002, 16 (02) :185-194
[26]   Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus [J].
Poynard, T ;
Bedossa, P ;
BioulacSage, P ;
Callard, P ;
Chevallier, M ;
Degott, C ;
Deugnier, Y ;
Fabre, M ;
Reynes, M ;
Voigt, JJ ;
Zafrani, ES ;
Metreau, JM ;
Valla, D ;
Opolon, P ;
Dhumeaux, D ;
Chaput, JC ;
Charlotte, F ;
Lemonnier, C ;
Babany, G ;
Agostini, H .
JOURNAL OF VIRAL HEPATITIS, 1997, 4 (03) :199-208
[27]   Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C [J].
Ramalho, F ;
Costa, A ;
Pires, A ;
Cabrita, P ;
Serejo, F ;
Correia, AP ;
Fatela, N ;
Clória, H ;
Lopes, J ;
Pinto, HC ;
Marinho, R ;
Raimundo, M ;
Velosa, J ;
Batista, A ;
De Moura, MC .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (01) :182-187
[28]   Nonalcoholic steatosis and steatohepatitis -: III.: Peroxisomal β-oxidation, PPARα, and steatohepatitis [J].
Reddy, JK .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2001, 281 (06) :G1333-G1339
[29]   Steatosis affects chronic hepatitis C progression in a genotype specific way [J].
Rubbia-Brandt, L ;
Fabris, P ;
Paganin, S ;
Leandro, G ;
Male, PJ ;
Giostra, E ;
Carlotto, A ;
Bozzola, L ;
Smedile, A ;
Negro, F .
GUT, 2004, 53 (03) :406-412
[30]   Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3 [J].
Rubbia-Brandt, L ;
Quadri, R ;
Abid, K ;
Giostra, E ;
Malé, PJ ;
Mentha, G ;
Spahr, L ;
Zarski, JP ;
Borisch, B ;
Hadengue, A ;
Negro, F .
JOURNAL OF HEPATOLOGY, 2000, 33 (01) :106-115